Join
Live feed
·
PRReleasevia Quantisnow
Alnylam Pharmaceuticals Inc. logo

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

ByQuantisnow·Wall Street's wire, on your screen.
ALNY· Alnylam Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALNY (Alnylam Pharmaceuticals Inc.) and more on Quantisnow.